Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep1190 | Steroid metabolism + action | ECE2017

Homo-dimerisation of cytochrome P450c17 resolves the conundrum of the dual activities of cytochrome P450c17

Holien Jessica , Parker Michael , Conley Alan , Corbin C Jo , Rodgers Raymond , Martin Lisandra

Reproduction requires the temporal and spacial control of specific and exact signals, delivered by locally regulated hormonal flux. In the case of androgen biosynthesis, cytochrome P450 17α-hydroxylase, 17,20-lyase (P450c17) is the key enzyme. However, P450c17 is a multi-functional P450, so, it synthesizes cortisol in the zona fascicula of the adrenal cortex and also androgen precursors in the adrenal zona reticularis and the gonads. The regulation of this dual activity h...

ea0029p931 | Female Reproduction | ICEECE2012

Conformational control of P450aromatase by lipid membrane interactions and protein associations

Martin L. , Praporski S. , Rodgers R. , Corbin C. , Conley A. , Mizrachi D.

Cytochrome P450 aromatase is a membrane bound enzyme that synthesises estrogens. This reaction involves electron delivery from NADPH via cytochrome P450 reductase (CPR). Little is known as to how the P450arom performs the aromatase reaction or how it associates with CPR in the endoplasmic reticulum (ER). In humans, there is only one P450arom, however pigs have three isozymes. The catalytic efficiency of one of these, the porcine gonadal P450arom, is much lower than the human a...

ea0084op-03-14 | Oral Session 3: Advanced Thyroid Cancer | ETA2022

Entrectinib in patients with ntrk fusion-positive (ntrk-fp) thyroid cancer: Updated data from startrk-2

W Bowles Daniel , Bazhenova Lyudmila , Hescot Segolene , Folprecht Gunnar , Daga Haruko , Massarelli Erminia , P Conley Anthony , Lamartina Livia , Lin Jessica , Ahn Eugene , Osborne Stuart , Heinzmann Sebastian , Carrizosa Daniel

Objectives: NTRK gene fusions are oncogenic drivers in many solid tumours, including thyroid cancers. In the phase 2 study STARTRK-2 (NCT02568267), entrectinib (a CNS-active tropomyosin receptor kinase [TRK] inhibitor) demonstrated efficacy in patients with NTRK-fp thyroid cancer (objective response rate [ORR]: 40%; clinical cut-off: 31 Oct 2018; n=5). We report updated data from a larger cohort with longer follow-up.Methods: A...